Skip to content

Irreversible electroporation (NanoKnife) for prostate cancer

How it works, who it has been studied in, results, side effects and what the guidelines say.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 18, 2026
Book a consultation
Drawing of the prostate in cross-section, seen from above, with a tumor on one side surrounded by four needle electrodes and the treated zone between them, away from the urethra and the erection nerves
On this page

Quick answer

Irreversible electroporation, known by the name of the device, NanoKnife, treats only the cancer area with electric pulses delivered through needles placed in the perineum.1 It does not rely on heat, which is why it has been studied as a way to spare the erection nerves and the sphincter.3 In the PRESERVE trial, 71% of 121 men had no cancer in the treated area one year later.5 The guidelines still consider the technique experimental: the European guideline recommends focal therapy only within clinical trials or registries.1,2

What it is and how it works

Irreversible electroporation is one of the focal therapy techniques, which treat only the part of the prostate where the tumor is, instead of removing or irradiating the whole gland.

Thin needles that act as electrodes are placed through the perineum, the skin between the scrotum and the anus. Short electric pulses of high voltage and low energy pass between them.1 The pulses open pores in the membranes of the cells in the treated area, and the cells cannot recover and die.10

What sets it apart from other energies is that the effect does not come from heat or cold. The authors describe the technique as destroying the tumor while sparing the erection nerve bundles and the sphincter, the muscle that holds urine.3 The first prospective study, in London, included men with the tumor at the front of the prostate.4

Who the technique has been studied in

A review by the Endourology Section of the European Association of Urology described the candidate in whom results were best:9

  • Intermediate-risk cancer, ISUP grade group 2 or 3 (Gleason 3+4 or 4+3)
  • Tumor confined to the prostate, on one side only and visible on MRI
  • PSA density below 0.15 to 0.20
  • A lesion small enough for the needles to cover safely, usually up to 2 cm

In the PRESERVE trial, the criteria were age over 50, ISUP 2 or 3, tumor confined to the prostate and a PSA of up to 15 ng/mL.5

To plan focal therapy, the tumor's location has to be well defined. In practice, that depends on MRI and a fusion biopsy, which show where the cancer is and whether there are other foci.

What the studies show

Studies of electroporation follow men with PSA, MRI and biopsy of the treated area. The main ones:

StudyMenResult
NEAT, London (2017)19No residual cancer in 61% on the control biopsy; clinically significant cancer in 33%4
PRESERVE, United States (2026)121, intermediate riskNegative biopsy in the treated area in 71% at 12 months, or 84% by the experts' consensus criterion5
Sydney (2023)229, followed for a median of 5 yearsFree of treatment failure in 84% at 5 years and 69% at 8 years; 17% went on to surgery or radiotherapy6
International registry (2024)411Clinically significant cancer in 24% of the 116 who had a repeat biopsy7

In the Sydney series, "failure" meant needing surgery or radiotherapy or having disease in the lymph nodes or elsewhere in the body. No man died of prostate cancer during the period.6

A review of 29 studies published in 2025 found cancer coming back in the treated area in 0% to 33% and outside it also in 0% to 33%. Between 0% and 37% of men needed further treatment.8 The review cited by the European guideline, with 19 studies and 1,452 men, had similar figures.1

The most cited weakness is cancer appearing outside the treated area, because prostate cancer often has more than one focus.9 Still-limited data, mostly from a single study, compared treating only the lesion with treating half of the prostate: cancer persisted in 25% and 8.6%, but treating only the lesion preserved erections better.9

Effects on urine, erections and complications

The main advantage studied for focal therapy is preserving function. In the electroporation studies:

  • Urine: in NEAT, all 16 men assessed had no urine leakage at 12 months.4 In the Sydney series, continence was 99% at 12 months.6 In the international registry, urinary symptoms worsened slightly in the first 3 months and then returned to baseline.7
  • Erections: in PRESERVE, 84% of men with good erections beforehand kept erections firm enough for penetration at 12 months.5 In Sydney, the share of men with erections sufficient for intercourse fell from 71% to 58%.6 In the review of 29 studies, the decline ranged from 3% to 22%.8
  • Complications: in PRESERVE, 12% had an adverse event of grade 3 or higher, and three of these events were attributed to the procedure.5 The review found complications needing further intervention in 1% to 19% of men and two cases of a fistula between the urethra and the rectum.8

The pages on continence and on erections and ejaculation compare these effects with those of other treatments.

Follow-up and if the cancer comes back

Because part of the prostate is still there, follow-up after any focal therapy takes more work than after surgery. Consensus statements on electroporation recommend a prostate biopsy at one year, PSA testing and serial MRI scans.11

If the cancer comes back or appears elsewhere, the options include another focal treatment, radical prostatectomy or radiotherapy. In the Sydney series, 17% of men went on to whole-gland treatment, usually about 3 years after electroporation.6

What the guidelines say

The two main guidelines treat electroporation, like the other focal therapies, as experimental:

GuidelineWhat it recommends
European (EAU, 2026)For low risk, focal therapy is likely overtreatment and should not be used outside trials. For intermediate risk, offer it only within clinical trials or registries (strong recommendation). For high risk, not recommended1
American (AUA/ASTRO, 2026)Tell patients with low- or intermediate-risk cancer that focal therapy remains investigational, without high-quality data comparing it with standard treatments. For high risk, do not recommend it outside a clinical trial2

Randomized trials are under way. In Sweden, PRIS is comparing electroporation with robotic prostatectomy and with radiotherapy in men with intermediate-risk disease.10 For low-risk disease, the option the guidelines recommend is active surveillance.1

When a second opinion helps

Many men come with a recommendation for focal therapy and want to understand whether it suits their case. It is worth talking to another specialist:

  • If your cancer is low risk and active surveillance has not been discussed
  • If the MRI and biopsy do not make clear where the tumor is or whether there are other foci
  • If you want to compare focal therapy with surgery and radiotherapy, which have longer follow-up
  • If your PSA or MRI has changed after focal therapy

A second opinion can be done entirely online, in English, with your test results sent in advance. The surgery or radiotherapy page helps compare whole-gland treatments.

Send your case

If you are having your prostate checked, with a raised PSA, an MRI or a biopsy, or you have already been diagnosed and would like my opinion before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

What is irreversible electroporation (NanoKnife)?

It is a form of focal therapy, which treats only the cancer area inside the prostate. High-voltage electric pulses pass between needle electrodes placed through the perineum and open pores in the cell membranes, and the cells die.1,10 NanoKnife is the name of the device used in the studies.5

Does electroporation burn the prostate?

No. The technique does not rely on heat, and the authors describe it as destroying the tumor while sparing the erection nerve bundles and the sphincter that holds urine.3

Who can have irreversible electroporation?

In the studies, the best results came from men with intermediate-risk cancer (ISUP 2 or 3), confined to the prostate, on one side only, visible on MRI and about 2 cm or smaller.9 In the PRESERVE trial, the criteria included age over 50, ISUP 2 or 3 and a PSA of up to 15 ng/mL.5

What are the results of irreversible electroporation?

In the PRESERVE trial of 121 men, 71% had no cancer in the treated area on the 12-month biopsy, or 84% by the experts' consensus criterion.5 In an Australian series of 229 men, 84% were free of treatment failure at 5 years and 69% at 8 years.6 No study has yet compared the technique with surgery or radiotherapy.2

Does electroporation affect erections and urine?

Urine leakage was rare in the studies. Erections may worsen in some men. In PRESERVE, 84% of men with good erections beforehand kept erections firm enough for penetration at 12 months.5 In a review of 29 studies, the decline in erections ranged from 3% to 22%.8

Can the cancer come back after electroporation?

Yes, inside or outside the treated area, because prostate cancer often has more than one focus. In the review of 29 studies, cancer came back in the treated area in 0% to 33%, and 0% to 37% of men needed further treatment.8,9 That is why follow-up with PSA, MRI and biopsy is essential.11

What do the guidelines say about irreversible electroporation?

The European guideline recommends offering focal therapy for intermediate-risk disease only within clinical trials or registries, and considers it overtreatment for low-risk disease.1 The American guideline says focal therapy remains investigational for low- and intermediate-risk disease.2

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  2. Eastham JA, Barocas DA, Chu CE, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026). J Urol. 2026;216(1):2-11. PubMed
  3. Durazo-Ruiz FO, Roldán-Testillano R, Rodriguez-Sanchez L, et al. Irreversible electroporation in focal therapy for prostate cancer: current status and future directions. Prostate Int. 2026;14(2):116-126. PubMed
  4. Valerio M, Dickinson L, Ali A, et al. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. J Urol. 2017;197(3 Pt 1):647-654. PubMed
  5. George AK, Miocinovic R, Patel AR, et al. Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. 2026;89(1):57-68. PubMed
  6. Scheltema MJ, Geboers B, Blazevski A, et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int. 2023;131 Suppl 4:6-13. PubMed
  7. Zhang K, Stricker P, Löhr M, et al. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer. Prostate Cancer Prostatic Dis. 2024;27(3):525-530. PubMed
  8. Cheng J, Adhami M, King D, et al. Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review. Transl Androl Urol. 2025;14(12):4012-4032. PubMed
  9. La Mura R, Maiolino G, Anract J, et al. Identifying the ideal candidate for irreversible electroporation in localized prostate cancer: a comprehensive narrative review from the EAU Section of Endourology. BJU Int. 2026;138(6):998-1006. PubMed
  10. Lantz A, Nordlund P, Falagario U, et al. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. Eur Urol Open Sci. 2023;51:89-94. PubMed
  11. Liu J, Ong S, Woon DTS, et al. Irreversible electroporation for partial gland ablation: clinical application and outcomes. Prostate Int. 2026;14(1):10-14. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides